AbbVie submits BLA for etentamig to FDA for multiple myeloma
The biologics license application supports a Phase 3 study showing improved response rates and progression-free survival versus standard therapies.
Latest AbbVie News & Updates
See the latest news and media coverage for AbbVie. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company
abbvie.com- Headquarters
- North Chicago, United States
- Company type
- Public company
- Number of employees
- 59,000+
- Industry
- Pharmaceuticals
Last updated
Latest news about AbbVie
In short: AbbVie closed its $10.9 billion Apogee deal and gained FDA approval for subcutaneous SKYRIZI in Crohn's disease.
Company announcements
AbbVie receives FDA approval for subcutaneous SKYRIZI induction
This allows home administration via on-body injector for Crohn's disease. The approval follows positive Phase 3 AFFIRM trial results demonstrating superior clinical remission rates.
AbbVie reports positive Phase 3 INTREPID trial results for lutikizumab
Lutikizumab met primary and secondary endpoints in moderate to severe hidradenitis suppurativa patients, showing improved symptoms and safety profile.
AbbVie presents new SKYRIZI and RINVOQ IBD data at ACG meeting
Phase 3 AFFIRM trial results for subcutaneous SKYRIZI in Crohn's disease and real-world evidence for RINVOQ highlight sustained disease control in complex patient populations.
Media coverage
AbbVie Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
AbbVie Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported sales was...
AbbVie lifts profit forecast as immunology drugs continue to fuel growth
AbbVie raised its annual profit forecast after topping Wall Street expectations for the third quarter on Friday, as booming sales of newer immunology drugs made...
AbbVie Submits FDA Application For Etentamig In Multiple Myeloma
AbbVie (ABBV) has submitted a Biologics License Application to the U.S. FDA for investigational Etentamig to treat adults with relapsed or refractory multiple myeloma, following...
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI ® (risankizumab-rzaa) for adults with...
Never miss news about AbbVie
Track AbbVie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
AbbVie competitors & trending companies
Browse news for competitors to AbbVie and other trending companies.